EUCTR2006-002614-36-IT进行中(未招募)不适用
Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine T4 soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised patients. - ND
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- IBSA
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Out-patients of both sexes; between 18 and 75 years of age; total thyroidectomy for any reasons, with consequent state of biological hypothyroidism; undetectable thyroglobulin levels 1 g/L or ng/mL and undetectable thyroglobulin autoantibodies by a sensitive immunoassay at screening; replacement/TSH suppressive therapy with T4 tablets stable for at least 3 months; adequate metabolic control; availability and possibility of taking part in the study; reasonable assumption of understanding the study and of reliability; written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •seriously compromised cardiac heart failure , hepatic, renal, respiratory functions; serious metabolic e.g. uncompensated diabetes mellitus , organs e.g. cirrhosis of the liver , endocrine or systemic diseases excluding the basic pathology ; neoplastic diseases active or in remission for less than 5 years excluding the basic pathology ; terminal condition; parenteral or assisted enteral feeding; serious psychiatric problems whether or not being treated or compromising the patient s reliability; non-therapeutic use of psychotropic substances; alcoholism; pregnancy, current or planned within the next 12 months; breast-feeding; hypersensitivity to the ingredients of the preparations; concomitant medications interfering with the study evaluations; participation in other clinical studies in the two months preceding screening; presumption of poor reliability/co-operation.
研究者
相似试验
进行中(未招募)
1 期
Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine (T4) soft capsules, in comparison to L-thyroxine tablets, in thyroidectomised patients.Post- operation hypothyroidismMedDRA version: 9.1Level: LLTClassification code 10021117Term: Hypothyroidism postoperativeEUCTR2006-002614-36-FRIBSA, Institut Biochimique SA205
进行中(未招募)
1 期
Multicentre, randomised, controlled, open-label, study comparing the efficacy and safety of slow repeated intravenous infusions of 2 doses of Doxorubicin Transdrug™ (DT) (20 mg/m² or 30 mg/m²) to those of best standard of care (BSC) in patients with advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib - ReLive Study - ReLiveEUCTR2011-002843-92-ITBioAlliance Pharma397
进行中(未招募)
1 期
Study comparing the efficacy and safety of doxorubicin Transdrug™ administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.EUCTR2011-002843-92-HUOnxeo390
进行中(未招募)
1 期
Study comparing the efficacy and safety of doxorubicin Transdrug™ administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.Advanced Hepatocellular Carcinoma (HCC)EUCTR2011-002843-92-ATOnxeo390
进行中(未招募)
1 期
Study comparing the efficacy and safety of doxorubicin TransdrugTM administered intravenously to the best available treatment in patient suffering from liver cancer after treatment with sorafenib.Advanced hepacellular carcinoma (HCC)EUCTR2011-002843-92-ESBioAlliance Pharma390
